School of Medicine


Showing 321-330 of 358 Results

  • Gabriel Velez, MD, PhD

    Gabriel Velez, MD, PhD

    Resident in Ophthalmology

    BioGabriel Velez is a PGY3 ophthalmology resident at Stanford. He received his bachelor’s degree in molecular biology from Winona State University in 2014. He completed his MD and PhD degrees at the University of Iowa. His PhD research focused on studying the structure of the calpain-5 (CAPN5) protein and its role in the development of Neovascular Inflammatory Vitreoretinopathy (NIV), a rare blinding eye disease. His research interests include translational proteomics, retinal disease, ocular oncology, structural biology, biophysical chemistry, drug design, and bioinformatics.

  • Aaran Vijayakumaran

    Aaran Vijayakumaran

    Postdoctoral Scholar, Ophthalmology

    BioAaran Vijayakumaran, PhD is a Postdoctoral Scholar at Stanford University School of Medicine, where he researches the cell biology of inherited Parkinson’s Disease in the Department of Biochemistry under Professor Suzanne Pfeffer.

    He completed his PhD at the University of Cambridge, applying volumetric electron microscopy and deep-learning based image segmentation to generate the first nanoscale map of the human airway epithelium. His doctoral work revealed how cellular architecture and metabolism remodel during differentiation, with a particular focus on the motile cilia, their rootlets, and their structural contacts with mitochondria and the consequences for mitochondrial metabolism. Beyond research, Aaran is active in the biotech and innovation ecosystem. He was awarded a scholarship to join EnterpriseTECH at Cambridge Judge Business School, served as an Investment Fellow Intern at Syncona, and worked as a Venture Builder Intern at Cambridge Future Tech and OmniBuds, a medical device startup. In these roles, he contributed to early-stage strategy, clinical trial planning, and commercial development.

  • Karen Wai, MD

    Karen Wai, MD

    Clinical Assistant Professor, Ophthalmology

    BioDr. Wai is a board-certified ophthalmologist and fellowship-trained vitreoretinal surgeon with Stanford Health Care Byers Eye Institute. She is also a clinical assistant professor of ophthalmology in the Department of Ophthalmology at Stanford University School of Medicine.

    Dr. Wai is a retina specialist who diagnoses and treats retinal and macular diseases, including age-related macular degeneration, diabetic retinopathy, retinal vascular occlusions (blockages), and retinal tears/detachments. The retina is a tissue layer in the back of the eye. It converts light into signals that the brain then interprets as images. The macula is the part of the retina responsible for central (straight ahead) vision. Diseases of the retina and macula can cause low vision and vision loss.

    Dr. Wai’s research interests include working with data from electronic health record databases to improve patient outcomes. She has researched morbidity and mortality (illness and death) rates in patients with retinal vein occlusions and retinal artery occlusions. A retinal vein occlusion is a blocked vein to the retina that can cause vision loss. A retinal artery occlusion is when an artery to the retina is blocked, which is also sometimes referred to as eye stroke. Dr. Wai has also examined the effects of systemic medications on the retina. She has won several ophthalmology awards, including the Heed Fellowship and Harvard Medical School’s Excellence in Clinical Instruction Resident Award.

    Dr. Wai has published in more than 80 peer-reviewed journals, including Ophthalmology, American Journal of Ophthalmology, and JAMA Ophthalmology. She has presented research at meetings and conferences around the United States.

    Dr. Wai is a member of the American Board of Ophthalmology.

  • Grzegorz Walkiewicz

    Grzegorz Walkiewicz

    Postdoctoral Scholar, Ophthalmology

    BioGrzegorz (Greg) Walkiewicz, PhD, is a neuroscientist with a strong background in retinal and neurodegenerative disease research. He completed his PhD at KU Leuven (Belgium), focusing on tau pathology and Alzheimer’s disease. His research explores the connection between brain and eye pathology, with particular interest in pTau, Aβ, and microglial activation. He has worked extensively with transgenic mouse models as well as human brain and retinal tissues. He recently joined Stanford University to investigate INPP5K-related mechanisms in retinal ganglion cell degeneration.

  • Brian A. Wandell

    Brian A. Wandell

    Isaac and Madeline Stein Family Professor and Professor, by courtesy, of Electrical Engineering, of Ophthalmology and of Education

    Current Research and Scholarly InterestsModels and measures of the human visual system. The brain pathways essential for reading development. Diffusion tensor imaging, functional magnetic resonance imaging and computational modeling of visual perception and brain processes. Image systems simulations of optics and sensors and image processing. Data and computation management for reproducible research.

  • Sean Ku Wang, MD

    Sean Ku Wang, MD

    Clinical Instructor, Ophthalmology

    Current Research and Scholarly InterestsImmune Response to Viral Vectors:
    Viral vectors such as adeno-associated virus (AAV) hold tremendous promise for treating genetic diseases. However, candidate AAV therapies have struggled to overcome dose-limiting immune responses, the underlying mechanisms for which are still unclear. We are investigating the cell types and pathways responsible for AAV-induced inflammation, with the goal of improving the safety and durability of gene therapy.

    Synthetic Promoters for Gene Therapy:
    Precise cell type targeting is critical for many gene therapy applications, yet engineering vectors that drive strong and specific expression remains challenging. Using multi-omics and artificial intelligence, we are designing new sequences to control gene activity, enabling robust expression in disease-relevant cell types while minimizing off-target effects.

    RNA Engineering and Delivery:
    RNA therapies have demonstrated success as vaccines and gene-silencing drugs, but their potential for gene editing and protein replacement is still being realized. We are exploring emerging RNA modalities and delivery systems with the aim of translating them into therapeutics and expanding the toolkit for non-viral gene therapy.